Vaccizone selects Exothera for process development and GMP manufacturing of its SARS‑CoV‑2 vaccine based on proprietary ASC technology.
July 6th 2022
BSCB Dev
Vaccizone, a vaccine development company focusing on innovative antigen delivery technology, selected Exothera S.A. to fast-track process development of its SARS‑CoV‑2 vaccine for European clinical trials